<?xml version="1.0" encoding="UTF-8"?>
<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema"
              xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema"
              xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema"
              xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
              xmlns:dct="http://purl.org/dc/terms/"
              xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
              xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/"
              xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/"
              xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/"
              xmlns:cja="http://www.elsevier.com/xml/cja/schema"
              xmlns:ja="http://www.elsevier.com/xml/ja/schema"
              xmlns:bk="http://www.elsevier.com/xml/bk/schema"
              xmlns:ce="http://www.elsevier.com/xml/common/schema"
              xmlns:mml="http://www.w3.org/1998/Math/MathML"
              xmlns:cals="http://www.elsevier.com/xml/common/cals/schema"
              xmlns:tb="http://www.elsevier.com/xml/common/table/schema"
              xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema"
              xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema"
              xmlns:xlink="http://www.w3.org/1999/xlink">
   <rdf:RDF>
      <rdf:Description rdf:about="http://dx.doi.org/10.1016/j.hnm.2021.200137">
         <dct:format>application/xml</dct:format>
         <dct:title>Association of lower circulating Spexin levels with higher body mass indices and glucose metabolic profiles in adult subjects in Egypt</dct:title>
         <dct:creator>Eman Salah Albeltagy</dct:creator>
         <dct:creator>Nashwa Mohamed Abd Elbaky</dct:creator>
         <dct:subject>
            <rdf:Bag>
               <rdf:li>Type 2 diabetes mellitus</rdf:li>
               <rdf:li>Spexin</rdf:li>
               <rdf:li>Obesity</rdf:li>
               <rdf:li>Unfovarable metabolic profile</rdf:li>
               <rdf:li>Insulin resistance</rdf:li>
            </rdf:Bag>
         </dct:subject>
         <dct:description>Human Nutrition &amp; Metabolism 27 (2022). doi:10.1016/j.hnm.2021.200137</dct:description>
         <prism:aggregationType>journal</prism:aggregationType>
         <prism:publicationName>Human Nutrition &amp; Metabolism</prism:publicationName>
         <prism:copyright>© 2021 The Authors. Published by Elsevier Inc.</prism:copyright>
         <dct:publisher>Elsevier Inc.</dct:publisher>
         <prism:issn>2666-1497</prism:issn>
         <prism:volume>27</prism:volume>
         <prism:coverDisplayDate>March 2022</prism:coverDisplayDate>
         <prism:doi>10.1016/j.hnm.2021.200137</prism:doi>
         <prism:url>http://dx.doi.org/10.1016/j.hnm.2021.200137</prism:url>
         <dct:identifier>doi:10.1016/j.hnm.2021.200137</dct:identifier>
         <bam:articleNumber>200137</bam:articleNumber>
         <oa:openAccessInformation>
            <oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus>
            <oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2021-12-13T11:28:08Z</oa:openAccessEffective>
            <oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
               <oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#Author</oa:sponsorType>
            </oa:sponsor>
            <oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by-nc-nd/4.0/</oa:userLicense>
         </oa:openAccessInformation>
         <cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY-NC-ND license.</cp:licenseLine>
      </rdf:Description>
   </rdf:RDF>
   <dp:document-properties>
      <dp:aggregation-type>Journals</dp:aggregation-type>
      <dp:version-number>S250.1</dp:version-number>
   </dp:document-properties>
   <ja:article docsubtype="fla" version="5.6" xml:lang="en">
      <ja:item-info>
         <ja:jid>HNM</ja:jid>
         <ja:aid>200137</ja:aid>
         <ce:article-number>200137</ce:article-number>
         <ce:pii>S2666-1497(21)00019-0</ce:pii>
         <ce:doi>10.1016/j.hnm.2021.200137</ce:doi>
         <ce:copyright type="other" year="2021">The Authors</ce:copyright>
      </ja:item-info>
      <ja:head>
         <ce:title id="title0010">Association of lower circulating Spexin levels with higher body mass indices and glucose metabolic profiles in adult subjects in Egypt</ce:title>
         <ce:author-group id="augrp0010">
            <ce:author id="au1"
                       orcid="0000-0001-5112-2815"
                       author-id="S2666149721000190-fdd2f5e45be8efa8c9747ad0167e5577">
               <ce:given-name>Eman Salah</ce:given-name>
               <ce:surname>Albeltagy</ce:surname>
               <ce:cross-ref refid="aff1">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="cor1">
                  <ce:sup loc="post">∗</ce:sup>
               </ce:cross-ref>
               <ce:e-address type="email"
                             xlink:href="mailto:eman.salah@azhar.edu.eg"
                             id="eadd0010">eman.salah@azhar.edu.eg</ce:e-address>
            </ce:author>
            <ce:author id="au2" author-id="S2666149721000190-30812b351286db5aede2dda5ff67b63d">
               <ce:given-name>Nashwa Mohamed</ce:given-name>
               <ce:surname>Abd Elbaky</ce:surname>
               <ce:cross-ref refid="aff2">
                  <ce:sup loc="post">b</ce:sup>
               </ce:cross-ref>
               <ce:e-address type="email" xlink:href="mailto:dr.nreda@gmail.com" id="eadd0015">dr.nreda@gmail.com</ce:e-address>
            </ce:author>
            <ce:affiliation id="aff1"
                            affiliation-id="S2666149721000190-f1a3545384c785f78861b49edc81fe49">
               <ce:label>a</ce:label>
               <ce:textfn>Department of Internal Medicine; Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Department of Internal Medicine</sa:organization>
                  <sa:organization>Faculty of Medicine for Girls</sa:organization>
                  <sa:organization>Al-Azhar University</sa:organization>
                  <sa:city>Cairo</sa:city>
                  <sa:country>Egypt</sa:country>
               </sa:affiliation>
               <ce:source-text id="srct0010">. Department of Internal Medicine; Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt</ce:source-text>
            </ce:affiliation>
            <ce:affiliation id="aff2"
                            affiliation-id="S2666149721000190-1eaab5167e1f983df08bd5899a6084b4">
               <ce:label>b</ce:label>
               <ce:textfn>Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Department of Clinical Pathology</sa:organization>
                  <sa:organization>Faculty of Medicine for Girls</sa:organization>
                  <sa:organization>Al-Azhar University</sa:organization>
                  <sa:city>Cairo</sa:city>
                  <sa:country>Egypt</sa:country>
               </sa:affiliation>
               <ce:source-text id="srct0015">, Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt</ce:source-text>
            </ce:affiliation>
            <ce:correspondence id="cor1">
               <ce:label>∗</ce:label>
               <ce:text>Corresponding author. Internal Medicine Department; Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.</ce:text>
               <sa:affiliation>
                  <sa:organization>Internal Medicine Department</sa:organization>
                  <sa:organization>Faculty of Medicine for Girls</sa:organization>
                  <sa:organization>Al-Azhar University</sa:organization>
                  <sa:city>Cairo</sa:city>
                  <sa:country>Egypt</sa:country>
               </sa:affiliation>
            </ce:correspondence>
         </ce:author-group>
         <ce:date-received day="7" month="7" year="2021"/>
         <ce:date-revised day="2" month="10" year="2021"/>
         <ce:date-accepted day="13" month="12" year="2021"/>
         <ce:abstract xml:lang="en" id="abs0010" view="all" class="author">
            <ce:section-title id="sectitle0010">Abstract</ce:section-title>
            <ce:abstract-sec id="abssec0010" view="all">
               <ce:section-title id="sectitle0015">Objectives</ce:section-title>
               <ce:simple-para id="abspara0010" view="all">Spexin (SPX) is a novel peptide hormone that lowers blood glucose levels and is protective against hepatic steatosis in diet induced obese mouse models. We hypothesized that higher circulating SPX levels would be associated with a lean BMI and a more favorable metabolic profile in humans. We aimed to investigate SPX levels and its association with obesity, glucose metabolic and cardiovascular factors in lean individuals compared to physical activity matched obese individuals.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abssec0015" view="all">
               <ce:section-title id="sectitle0020">Methods</ce:section-title>
               <ce:simple-para id="abspara0015" view="all">This cross-sectional study was performed with the participation of 135 individuals with various BMIs. Anthropometric and fasting metabolic parameters were determined in all participants and serum SPX levels were measured using ELISA.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec role="results" id="abssec0020" view="all">
               <ce:section-title id="sectitle0025">Results</ce:section-title>
               <ce:simple-para id="abspara0020" view="all">The levels of serum SPX were significantly lower in obese individuals than in those with overweight or normal-weight (P &lt; 0.001). Additionally, SPX levels in the subgroup with diabetes was lower than those with normal glycemia (P &lt; 0.001)<ce:bold>.</ce:bold> On spearman correlation analysis, SPX levels were negatively associated with adiposity markers,FBS,IR,and unfavorable lipid profile, and positively associated with HDL-c(p &lt; 0.001). On multiple stepwise linear regression analysis, the only covariates independently associated with SPX were IR and BMI. Additionally, in fully adjusted model, the odds ratio of T2DM with serum concentrations of SPX was approximately 0.912(95%CI 0.085–9.781, P &lt; 0.001) compared to those with normal glycemia.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec role="conclusion" id="abssec0025" view="all">
               <ce:section-title id="sectitle0030">Conclusion</ce:section-title>
               <ce:simple-para id="abspara0025" view="all">SPX is a beneficial novel hormone whose circulating levels is significantly lower in obese subjects, and associated with unfavorable metabolic profiles. These data can suggestive of a potential role of SPX as a useful biomarker of the metabolic health status of one individual.</ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract class="author-highlights" xml:lang="en" id="abs0015" view="all">
            <ce:section-title id="sectitle0035">Highlights</ce:section-title>
            <ce:abstract-sec id="abssec0030" view="all">
               <ce:simple-para id="abspara0030" view="all">
                  <ce:list id="ulist0010">
                     <ce:list-item id="u0010">
                        <ce:label>•</ce:label>
                        <ce:para id="p0010" view="all">Spexin, a beneficial novel hormone, has potential implications in obesity and its related disorders.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="u0015">
                        <ce:label>•</ce:label>
                        <ce:para id="p0015" view="all">Spexin levels are significantly lower in obese subjects and associated with unfavorable metabolic profiles.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="u0020">
                        <ce:label>•</ce:label>
                        <ce:para id="p0205" view="all">Optimizing spexin levels may improve obesity and its related metabolic disorders.</ce:para>
                     </ce:list-item>
                  </ce:list>
               </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
            <ce:section-title id="sectitle0040">Keywords</ce:section-title>
            <ce:keyword id="kwrd0010">
               <ce:text>Type 2 diabetes mellitus</ce:text>
            </ce:keyword>
            <ce:keyword id="kwrd0015">
               <ce:text>Spexin</ce:text>
            </ce:keyword>
            <ce:keyword id="kwrd0020">
               <ce:text>Obesity</ce:text>
            </ce:keyword>
            <ce:keyword id="kwrd0025">
               <ce:text>Unfovarable metabolic profile</ce:text>
            </ce:keyword>
            <ce:keyword id="kwrd0030">
               <ce:text>Insulin resistance</ce:text>
            </ce:keyword>
         </ce:keywords>
         <ce:keywords xml:lang="en" class="abr" id="kwrds0015" view="all">
            <ce:section-title id="sectitle0045">Abbreviations</ce:section-title>
            <ce:keyword id="kwrd0035">
               <ce:text>FPS</ce:text>
               <ce:keyword id="kwrd0040">
                  <ce:text>fasting blood sugar</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0045">
               <ce:text>HOMA-IR</ce:text>
               <ce:keyword id="kwrd0050">
                  <ce:text>homeostatic model of insulin resistance</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0055">
               <ce:text>QUICKI</ce:text>
               <ce:keyword id="kwrd0060">
                  <ce:text>quantitative insulin sensitivity check index</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0065">
               <ce:text>TC</ce:text>
               <ce:keyword id="kwrd0070">
                  <ce:text>total cholesterol</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0075">
               <ce:text>TG</ce:text>
               <ce:keyword id="kwrd0080">
                  <ce:text>triglyceride</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0085">
               <ce:text>HDL-c</ce:text>
               <ce:keyword id="kwrd0090">
                  <ce:text>high-density lipoprotein-cholesterol</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0095">
               <ce:text>LDL-c</ce:text>
               <ce:keyword id="kwrd0100">
                  <ce:text>low-density lipoprotein cholesterol</ce:text>
               </ce:keyword>
            </ce:keyword>
            <ce:keyword id="kwrd0105">
               <ce:text>SPX</ce:text>
               <ce:keyword id="kwrd0110">
                  <ce:text>spexin</ce:text>
               </ce:keyword>
            </ce:keyword>
         </ce:keywords>
      </ja:head>
   </ja:article>
</doc:document>
